Study of SU11248 in Men With Advanced Prostate Cancer
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
- There are nearly 30,000 deaths per year in the United States from prostate cancer,
making this a large and important target patient population for new cancer treatments.
- SU011248 is an exciting, new, experimental drug that inhibits a number of proteins, or
more specifically receptor tyrosine kinases, in tumor cells. These proteins are active
in cellular pathways that are important for development and growth of a variety of
different cancers. The targets of SU011248 include the receptors for vascular
endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and others. By
blocking the VEGF and PDGF pathways, SU011248 can induce death of the blood vessels that
nourish the cancer cells and death of the cancer cells themselves.
- SU011248 has demonstrated significant anti-tumor activity in renal cell carcinoma,
gastrointestinal stromal tumors, and other cancers. Its effect against prostate cancer
has not been studied to date.
- This study is directed at two populations of men with advanced prostate cancer:
1. Men with advanced prostate cancer who have a rising PSA despite hormone therapy,
but have not yet received any chemotherapy.
2. Men with metastatic prostate cancer who have received prior chemotherapy (with a
docetaxel-based regimen) and have increasing disease following chemotherapy.
- Men in this study will receive SU011248 on a six-week repeating schedule, with four
weeks of daily treatment followed by a two-week rest. The goals of the study are:
1. to determine whether SU011248 is an important therapeutic agent in men with
advanced prostate cancer, and
2. to identify predictive markers of anti-cancer activity within individual subjects
that would allow selective treatment of appropriate subjects in the future.